These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1725238)
1. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein. Zaghouani H; Hall B; Shah H; Bona C Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238 [No Abstract] [Full Text] [Related]
2. Antigenicity of three synthetic peptides from the C-terminus of HIV-1 gp 120 correlates with the fragmentation pattern obtained in FAB mass spectrometry. Streckert HJ; Weber C; Müller D Intervirology; 1993; 36(3):128-33. PubMed ID: 7512081 [TBL] [Abstract][Full Text] [Related]
3. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein. Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947 [TBL] [Abstract][Full Text] [Related]
4. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797 [TBL] [Abstract][Full Text] [Related]
5. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416 [TBL] [Abstract][Full Text] [Related]
6. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels. Warren RQ; Wolf H; Zajac RA; Boswell RN; Kanda P; Kennedy RC J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780 [TBL] [Abstract][Full Text] [Related]
7. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes. Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842 [TBL] [Abstract][Full Text] [Related]
8. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572 [TBL] [Abstract][Full Text] [Related]
9. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data. Becker Y Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457 [TBL] [Abstract][Full Text] [Related]
10. Specificity of anti-peptide antibodies elicited against synthetic peptides mimicking conserved regions of HIV1 envelope glycoprotein. Clerget-Raslain B; Benjouad A; van Rietschoten J; Montagnier L; Rochat H; Bahraoui E Res Virol; 1991; 142(6):423-38. PubMed ID: 1803410 [TBL] [Abstract][Full Text] [Related]
11. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. Neurath AR; Strick N; Li YY; Jiang S AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138 [TBL] [Abstract][Full Text] [Related]
12. Fine specificity of the murine antibody response to HIV-1 gp160 determined by synthetic peptides which define selected epitopes. Wolf H; Warren RQ; Stunz GW; Shuler KR; Kanda P; Kennedy RC Mol Immunol; 1992; 29(7-8):989-98. PubMed ID: 1378936 [TBL] [Abstract][Full Text] [Related]
13. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. Warren RQ; Wolf H; Shuler KR; Eichberg JW; Zajac RA; Boswell RN; Kanda P; Kennedy RC J Virol; 1990 Feb; 64(2):486-92. PubMed ID: 2404138 [TBL] [Abstract][Full Text] [Related]
14. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Dis Markers; 1991; 9(1):51. PubMed ID: 1742945 [No Abstract] [Full Text] [Related]
15. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network. Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300 [TBL] [Abstract][Full Text] [Related]
17. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425 [No Abstract] [Full Text] [Related]
18. How antibodies block HIV infection: paths to an AIDS vaccine. Putney S Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693 [TBL] [Abstract][Full Text] [Related]
19. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694 [TBL] [Abstract][Full Text] [Related]
20. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types. Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157 [No Abstract] [Full Text] [Related] [Next] [New Search]